Biodesix Inc
$ 13.14
-1.28%
17 Apr - close price
- Market Cap 134,527,000 USD
- Current Price $ 13.14
- High / Low $ 13.80 / 13.00
- Stock P/E N/A
- Book Value -0.30
- EPS -4.67
- Next Earning Report 2026-05-12
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.19 %
- ROE -3.83 %
- 52 Week High 20.21
- 52 Week Low 3.44
About
Biodesix, Inc. operates a data-driven diagnostic solutions company in the United States. The company is headquartered in Boulder, Colorado.
Analyst Target Price
$30.00
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-27 | 2025-10-30 | 2025-08-07 | 2025-05-06 | 2025-02-27 | 2024-11-05 | 2024-08-07 | 2024-05-08 | 2024-03-01 | 2023-11-07 | 2023-08-07 | 2023-05-11 |
| Reported EPS | -0.49 | -1.16 | -0.08 | -0.08 | -0.06 | -0.07 | -0.08 | -0.14 | -0.1 | -0.14 | -0.17 | -0.24 |
| Estimated EPS | -0.866 | -0.0593 | -0.07 | -0.07 | -0.0667 | -0.07 | -0.09 | -0.14 | -0.11 | -0.15 | -0.21 | -0.24 |
| Surprise | 0.376 | -1.1007 | -0.01 | -0.01 | 0.0067 | 0 | 0.01 | 0 | 0.01 | 0.01 | 0.04 | 0 |
| Surprise Percentage | 43.418% | -1856.1551% | -14.2857% | -14.2857% | 10.045% | 0% | 11.1111% | 0% | 9.0909% | 6.6667% | 19.0476% | 0% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-12 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -1.26 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: BDSX
2026-04-10 07:39:32
Aberdeen Group plc has acquired a new stake of 262,425 shares in Biodesix, Inc. (NASDAQ:BDSX) worth approximately $1.78 million, representing about 3.3% of the company. This comes as Biodesix reported better-than-expected earnings for Q4, with a smaller loss and higher revenue than anticipated. Insider activity also shows significant buying by Director Jack W. Schuler, while institutional investors hold 20.96% of the stock.
2026-04-09 20:10:13
Biodesix (NASDAQ: BDSX) has released details for its 2026 Annual Meeting of Stockholders, to be held virtually on May 19, 2026. Key proposals include the election of two Class III directors, an advisory vote on 2025 executive compensation, a non-binding advisory vote on the frequency of future say-on-pay votes (with the board recommending annually), and the ratification of KPMG LLP as the independent auditor for 2026. The proxy statement also details executive and director compensation, including 2025 salary increases, bonuses, equity awards, and new severance agreements.
2026-04-09 17:10:13
Biodesix (NASDAQ: BDSX) has been recognized for the third consecutive year with the 2026 USA TODAY Top Workplaces award, announced on April 9, 2026. This prestigious award is based on confidential employee feedback collected by Energage, highlighting Biodesix's strong employee engagement, meaningful work, and a people-first culture. CEO Scott Hutton credits the trust, collaboration, and shared ownership among team members for this consistent recognition, emphasizing its importance in driving high performance and patient impact.
2026-04-09 00:40:32
Biodesix will present seven abstracts, including two oral sessions, at the American Association for Cancer Research (AACR) Annual Meeting. The presentations will cover advancements in liquid biopsy, next-generation sequencing, and multi-omic approaches for cancer monitoring and biomarker detection, showcasing capabilities in blood- and tissue-based testing. Key areas include automated clinical myeloid panels, NSCLC variant analysis, and molecular residual disease (MRD) monitoring through collaborative efforts.
2026-04-06 22:40:18
Biodesix, Inc. (Nasdaq: BDSX) announced it will present seven abstracts, including two oral sessions, at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA, from April 17 - 22, 2026. These presentations will showcase the company's capabilities in blood- and tissue-based testing for oncology, focusing on novel proteomic and genomic approaches for therapeutic selection, response monitoring, and Molecular Residual Disease (MRD) testing. The company also highlighted advancements in its pipeline, including a new clinical myeloid panel on the Thermo Fisher Ion Torrent™ Genexus™ System.
2026-04-06 19:10:09
Biodesix, Inc. will present new research on a novel diagnostic test at the American Association for Cancer Research (AACR) annual meeting in 2026. This Colorado-based biotech company's new test aims to detect cancer at the cellular level using advanced molecular analysis. The goal is to improve early detection and patient outcomes, representing a significant advancement in cancer diagnostics.
